Castle Biosciences (CSTL) Retained Earnings (2018 - 2026)

Castle Biosciences has disclosed Retained Earnings across 9 years of filings, most recently posting $711.1 million for Q2 2026.

• In Q2 2026, Retained Earnings rose 5.08% year-over-year to $711.1 million; the TTM figure through Jun 2026 stood at $711.1 million (up 5.08% YoY), while the FY2025 annual figure was $694.9 million, up 5.97% from the prior year.
• Retained Earnings came in at $711.1 million for Q2 2026 at Castle Biosciences, up from $700.3 million in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $711.1 million in Q2 2026 to a low of $515.7 million in Q1 2022.
• Average Retained Earnings over 5 years is $624.8 million, with a median of $629.7 million recorded in 2024.
• Year-over-year, Retained Earnings climbed 11.57% in 2023 and rose 5.08% in 2026.
• Over 5 years, Retained Earnings stood at $560.4 million in 2022, then gained by 8.76% to $609.5 million in 2023, then rose by 7.58% to $655.7 million in 2024, then rose by 5.97% to $694.9 million in 2025, then climbed by 2.34% to $711.1 million in 2026.
• Per Business Quant data, the three most recent Retained Earnings figures were $711.1 million in Q2 2026, $700.3 million in Q1 2026, and $694.9 million in Q4 2025.